Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00334022
Status:
COMPLETED
Last Update Posted:
2012-06-05
First Post:
2006-06-02
Brief Title:
Fuzeon Viral Decay Pilot Study
Sponsor:
Canadian Immunodeficiency Research Collaborative
Organization:
Canadian Immunodeficiency Research Collaborative
Study Overview
Official Title:
A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In order to better understand the sources and the mechanisms of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs we propose to examine the effect of co-administration of enfuvirtide an entry inhibitor of HIV on diminution of the size of the viral reservoir in infected individuals who are receiving effective antiviral therapy for extended periods of time 5 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None